Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing email@example.com or calling +44 (0)1707 367554.
Expert perspectives on HEMLIBRA and the future of haemophilia A care
The latest from global congresses and symposia, where experts from around the world have highlighted the challenges faced by people with haemophilia A. With the advent of modern therapies, such as HEMLIBRA, we are seeing a shift in focus towards improving all aspects of patients’ lives, beyond bleed protection.
Hear healthcare professionals discuss the future of haemophilia A care, share first-hand treatment experience with HEMLIBRA, present patient case studies and explore data findings.
ASH 2021 and EAHAD 2022
HEMLIBRA highlights from the latest American Society of Hematology (ASH) and European Association for Haemophilia and Allied Disorders (EAHAD) congresses.
View digital summaries of surgical experience with HEMLIBRA, data on use of HEMLIBRA in older patients with comorbidities and the updated safety evaluation of HEMLIBRA prophylaxis.
HEMLIBRA highlights from the latest International Society on Thrombosis and Haemostasis (ISTH) Congress. Learn how HEMLIBRA is helping patients with severe haemophilia A achieve the ‘zero bleeds milestone'. View real-world case studies, expert analyses and clinical findings in this collection of posters and video presentations.
ASH, American Society of Hematology; EAHAD, European Association for Haemophilia and Allied Disorders; FVIII, Factor VIII; ISTH, International Society on Thrombosis and Haemostasis; MHRA, Medicines and Healthcare products Regulatory Agency.
Date of preparation: May 2022